Toxoplasma gondii is a common parasite of animals and frequent cause of accidental infection in humans. Acute infections are generally controlled by the immune response, but persistent chronic infection ensues due to survival of semi-dormant stages called bradyzoites that reside within tissue cysts. In immunocompromised patients, rupture of the tissue cysts releases bradyzoites that can convert back to rapidly replicating tachyzoites, a process that goes unrestricted due to decreased T-cell immunity. The potential for reactivation presents a continued risk to immunocompromised patients due to the fact that neither the immune system nor antibiotics can eradicate chronic infections. As such, there is still a need to understand fundamental mechanisms of pathogenicity in order to develop more effective interventions. One of the key mediators of innate and adaptive immunity to T. gondii is the production of interferons that activate cells to control the parasite through a variety of mechanisms including nutrient depletion, targeting the parasitophorous vacuole for destruction, or growth inhibition. As one of the world's most successful parasites, it is not surprising that T. gondii has developed active mechanisms to block these immune control pathways. Our studies seek to define the molecular bases of how T. gondii blocks or subverts interferon signaling to overcome host defenses. In the prior funding period, we identified a secretory parasite protein that traffics to the host nucleus where it binds to the transcription factor STAT1 and recruits a chromatin modifying complex to block gene expression induced by both type I (IFN-?) and type II (IFN-?) interferons. Our prior studies demonstrate that the ability of the parasite to block type II IFN is primarily important in the acute infection while its ability to subvert type I IFN is key in the central nervous system during chronic infection. We have also recently identified a second secreted effector that also traffics to the host cell nucleus and blocks the type I IFN pathway. The proposed studies will explore the molecular mechanisms by which these effectors inhibit IFN signaling by bradyzoites and thus assure survival of tissue cysts that are responsible for chronic infection.

Public Health Relevance

Infection with Toxoplasma gondii is widespread and it poses great risk to individuals should their immune system become compromised. Successful identification of pathogenetic mechanisms utilized by T. gondii to block the immune response may enable future studies designed to improve treatment of toxoplasmosis, including in AIDS patients.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project (R01)
Project #
Application #
Study Section
HIV Coinfections and HIV Associated Cancers Study Section (HCAC)
Program Officer
Joy, Deirdre A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Washington University
Schools of Medicine
Saint Louis
United States
Zip Code
Cabral, Gabriel R de Abreu; Wang, Zi T; Sibley, L D et al. (2018) Inhibition of Nitric Oxide Production in Activated Macrophages Caused by Toxoplasma gondii Infection Occurs by Distinct Mechanisms in Different Mouse Macrophage Cell Lines. Front Microbiol 9:1936
McFarland, Ross; Wang, Zi Teng; Jouroukhin, Yan et al. (2018) AAH2 gene is not required for dopamine-dependent neurochemical and behavioral abnormalities produced by Toxoplasma infection in mouse. Behav Brain Res 347:193-200
Matta, Sumit K; Patten, Kelley; Wang, Quiling et al. (2018) NADPH Oxidase and Guanylate Binding Protein 5 Restrict Survival of Avirulent Type III Strains of Toxoplasma gondii in Naive Macrophages. MBio 9:
Radke, Joshua B; Carey, Kimberly L; Shaw, Subrata et al. (2018) High Throughput Screen Identifies Interferon ?-Dependent Inhibitors of Toxoplasma gondii Growth. ACS Infect Dis 4:1499-1507
Brown, Kevin M; Long, Shaojun; Sibley, L David (2018) Conditional Knockdown of Proteins Using Auxin-inducible Degron (AID) Fusions in Toxoplasma gondii. Bio Protoc 8:
Shen, Bang; Brown, Kevin; Long, Shaojun et al. (2017) Development of CRISPR/Cas9 for Efficient Genome Editing in Toxoplasma gondii. Methods Mol Biol 1498:79-103
Jones, Nathaniel G; Wang, Qiuling; Sibley, L David (2017) Secreted protein kinases regulate cyst burden during chronic toxoplasmosis. Cell Microbiol 19:
Hakimi, Mohamed-Ali; Olias, Philipp; Sibley, L David (2017) Toxoplasma Effectors Targeting Host Signaling and Transcription. Clin Microbiol Rev 30:615-645
Peyron, Francois; Mc Leod, Rima; Ajzenberg, Daniel et al. (2017) Congenital Toxoplasmosis in France and the United States: One Parasite, Two Diverging Approaches. PLoS Negl Trop Dis 11:e0005222
Wang, Zi T; Verma, Shiv K; Dubey, Jitender P et al. (2017) The aromatic amino acid hydroxylase genes AAH1 and AAH2 in Toxoplasma gondii contribute to transmission in the cat. PLoS Pathog 13:e1006272

Showing the most recent 10 out of 23 publications